Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib as 2nd Line Treatment in Advanced Renal Cell Carcinoma After Checkpoint Inhibitors
NCT03945773Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jan 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Ipsen. Started Jan 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03945773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945773.